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Clinical and biochemical correlates of starting “daily” hemodi- Hemodialysis patients dialyze intermittently and,
alysis. therefore, experience repetitive cycling of body water
Background. Daily hemodialysis has been proposed to im- content, serum osmolality, and dialyzable body constit-prove outcomes for patients with end-stage renal disease. There
uents. Such cycling is an abnormal physiologic state andhas been increasing evidence that daily hemodialysis might
may contribute to morbidity and mortality among hemo-have potential advantages over intermittent dialysis. However,
despite these potential advantages, daily hemodialysis is infre- dialysis patients [1]. It has been proposed that uremia
quently used in the United States, and published accounts on should be treated by frequent dialysis to reduce the mag-
the technique are few. nitude of such swings in body composition [1, 2]. Despite
Methods. We describe patient outcomes after increasing the potential advantages of daily hemodialysis, currently,their hemodialysis frequency from three to six times per week
hemodialysis for end-stage renal disease (ESRD) is usu-in a cohort of 72 patients treated at nine centers during 1972
ally performed three times per week. Data from theto 1996. Analyses of predialysis blood pressure and laboratory
parameters from 6 months before until 12 months after starting United States Renal Data System show that in 1993,
frequent hemodialysis used a repeated-measures statistical only 0.3% of prevalent hemodialysis patients dialyzed
technique. more than three times per week [3].
Results. Predialysis systolic and diastolic blood pressures fell
There may be other advantages to daily hemodialysis.by 7 and 4 mm Hg, respectively, after starting frequent hemodi-
There is increasing evidence of the beneficial effects ofalysis (P 5 0.02). Reductions were greatest among patients
greater delivered doses of dialysis on patient morbiditybeing treated with antihypertensive medications, despite a re-
duction in their dosage of medications. Postdialysis weight fell and mortality [4, 5]. Hemodialysis is most efficient at
by 1.0% within one month of starting frequent hemodialysis removing solute early in the course of an individual treat-
and improved control of hypertension. After the initial drop, ment, and frequent, short hemodialysis sessions can
postdialysis weight increased at a rate of 0.85 kg per six months.
achieve greater urea removal when the total treatmentSerum albumin rose by 0.29 g/dl (P , 0.001) between months
time per week is constant [6, 7].1 to 12 of treatment with daily hemodialysis. Hematocrit rose
Despite an increasing interest in daily hemodialysis,by 3.0 percentage points (P 5 0.02) among patients (N 5 56)
not treated with erythropoietin during this period. Two years because of recognition of potential benefits of this tech-
after the start of daily hemodialysis, Kaplan–Meier analyses nique, published accounts of experience with the tech-
showed a patient survival of 93%, a technique survival of 77%, nique are few and describe limited experience [2, 8–11].
and an arteriovenous fistula patency of 92%. Vascular access
To describe the accumulated experience, we report onpatency was excellent despite more frequent use of the access.
new analyses of data collected from centers known toConclusions. These results suggest that in certain patients,
have treated patients with daily hemodialysis for overdaily hemodialysis might have advantages over three times per
week hemodialysis. one year. Throughout this article the use of frequent
hemodialysis is referred to as daily hemodialysis. In fact,
the median frequency of dialysis in the 72 patients de-
1 Current address: Regional Nephrology Unit, Belfast City Hospital, scribed in this study was six times per week (78% of
Belfast BT9 7AB, Northern Ireland, United Kingdom.
patients), and only 14% dialyzed on a daily basis.
Key words: dialysis frequency, uremia, end-stage renal disease, renal
replacement therapy.
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ysis (the centers, principal investigators, and the number of exclusion of patients from this center and all patients
with less than one-year experience of daily hemodialysisof patients at each site are listed in the Acknowledgments
section). Data for 72 study patients were collected by on the outcome. First, patient and technique survival
was reanalyzed after excluding this center. Second, pa-dialysis unit staff in each center. After data entry and
quality control, the data were transferred for analysis to tient and technique survival was reanalyzed with all cen-
ters included, but with the analysis starting at one yearAnn Arbor, Michigan, USA. Database management and
analyses used the SAS statistical system (version 6.12; after switching to daily hemodialysis. Patient and tech-
nique survival was compared between patients treatedSAS Institute, Cary, NC, USA).
with daily hemodialysis at home versus in a dialysis cen-
Statistical analysis ter using the log-rank statistic.
For vascular access survival, the dependent variableAnalyses of predialysis blood pressure and laboratory
values at times before and after switching from three in the analysis was time from start of daily hemodialysis
until the first vascular access failure identified in thetimes per week hemodialysis to daily hemodialysis used
a repeated-measures technique. Generalized linear re- medical record; observations were censored at death,
transplantation, return to conventional hemodialysis, orgression models were fitted using the “PROC MIXED”
procedure of the SAS statistical program. Each model the end of patient follow-up. A vascular access failure
was considered to have occurred when the medical re-allowed estimation of the trend (slope) in the parameter
of interest while the patient was on conventional center cord indicated that an access thrombosis or infection
developed, when access blood flow was judged insuffi-hemodialysis, allowed the average level to change at the
time of switch to daily hemodialysis, and allowed an cient to allow the prescribed dialysis treatment, or when
a surgical procedure on the access was performed.estimation of the trend after switching to daily hemodial-
ysis. The analysis was confined to the period from 6 For the analysis of hospitalization, the dependent vari-
able was time from the start of daily hemodialysis untilmonths before to 12 months after switching to daily he-
modialysis. The time points during this period were 3 the first hospitalization. The analysis was censored at
and 6 months before switching to daily hemodialysis, death, transplantation, return to conventional hemodial-
the time of switch, and 1, 3, 6, 9, and 12 months after ysis, or end of patient follow-up. A sensitivity analysis
switching. considered an unplanned return to conventional hemodi-
Analysis of the proportions of patients receiving anti- alysis as an event.
hypertensive agents and phosphate binders between 1
month before and until 12 months after switching to
RESULTSdaily hemodialysis used McNemar’s test for the equality
Data were available for 72 patients who started dailyof proportions in matched samples.
hemodialysis between 1972 and 1996 (the median yearAnalyses of patient survival, technique survival, time
was 1988). The median patient age was 47 years (rangeto first hospitalization, and vascular access failure from
13 to 70 years). Seventy-four percent were male, andthe time of starting daily hemodialysis were made by the
97% were of the white race. The cause of ESRD wasKaplan–Meier method. An intent-to-treat method was
glomerulonephritis in 48.6% of cases, polycystic kidneyused to analyze patient survival so that for the purposes
disease in 23.6%, interstitial nephritis in 8.3%, diabetesof the analyses, the original treatment assignment was
mellitus in 6.9%, and other causes in 12.6%.unchanged if the patient stopped daily hemodialysis and
The median period of treatment with conventionalresumed conventional hemodialysis. Each death was
hemodialysis prior to switching to daily hemodialysis wasconsidered an event, and observations were censored at
24 months; 81% of patients were treated with conven-the end of follow-up or at transplantation.
tional hemodialysis for more than 6 months and 67%Both death and restarting conventional hemodialysis
for longer than 12 months. Patients were treated withwere considered as events for analyses of technique sur-
daily hemodialysis for a median of 24 months (range 4vival; observations were censored at the end of follow-
to 158 months); 32% of patients were treated with dailyup and at transplantation. However, in three instances,
hemodialysis for less than 12 months. The median predi-patients were switched to daily hemodialysis and then
alysis blood urea nitrogen (BUN) value at three monthsback to conventional dialysis as part of a planned study.
before starting daily hemodialysis was 98 mg/dl, and atFollow-up of technique survival for these patients was
three months after starting daily hemodialysis, it was 79censored on the date of their planned return to treatment
mg/dl. Details of the dialysis prescription before andwith conventional hemodialysis.
then on starting daily hemodialysis are shown in Table 1.One center (Catanzaro, Italy) provided only data on
The most common reason given for starting daily he-patients who had survived for at least one year after
modialysis was lifestyle or employment (37.9%). Patientsswitching to daily hemodialysis. Separate sensitivity anal-
yses were therefore performed to determine the effect also started daily hemodialysis to allow better control of
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Table 1. Dialysis prescription before (conventional) and on starting daily hemodialysis
Parameter Conventional Daily
(median value unless stated) hemodialysis hemodialysis
Number of treatments per week (range) 3 (2–4) 6 (5–7)
Duration of each hemodialysis treatment hours (range) 4.0 (2.5–8.0) 1.5 (1.1–3.0)
Total hemodialysis treatment time per week hours 12 10.5
Percent synthetic or semisynthetic dialyzer membrane 42 51
Dialyzer membrane surface area m2 (range) 1.3 (0.9–2.1) 1.3 (0.9–2.1)
Dialyzer blood flow rate ml /min 275 285
Dialysate flow rate ml /min 500 500
Percent HCO32 dialysate 83 92
Percent single pass dialysate circulation 95 56
Table 2. Levels and trends before and after change from conventional to daily hemodialysis (HD) for blood pressure,
weight, albumin, and hematocrit
Conventional hemodialysis
Start of daily HD
Daily hemodialysis
Change per Mean prior to Change per
Parameter 6 months P value starting daily HD Change P value 6 months P value
Blood pressure (BP)
All patients
Predialysis systolic BP 22 0.93 144 27 0.02 27 0.21
Predialysis diastolic BP 0 0.93 86 24 0.02 24 0.07
Subgroup of patients treated with antihypertensive
medications (N 5 35)
Predialysis systolic BP 24 0.49 163 213 ,0.01 27 0.28
Predialysis diastolic BP 23 0.37 94 27 0.02 23 0.33
Weight
Post-dialysis weight kg 20.44 0.18 63.3 20.63 0.03 0.85 0.02
Albumin
Serum albumin g/dl 20.18 0.01 3.88 0.2 ,0.01 0.1 ,0.001
Hematocrit %
All patients 0.2 0.71 27.9 1.7 0.002 0.9 0.31
Subgroup of patients not treated with erythropoietin
(N 5 56) 0.2 0.72 27.5 1.8 0.004 1.5 0.02
hypertension (13.8%), to avoid intradialytic hypotension Thereafter, the postdialysis weight increased by 0.85 kg
per six months (P 5 0.02) while the patients were treated(15.5%), because of other medical reasons (24.1%), be-
with daily hemodialysis.cause of preference, or as part of a planned study (8.6%).
After switching to daily hemodialysis, 58% of patients
Trends in blood pressure(N 5 42) dialyzed at home, and 42% (N 5 30) dialyzed
The changes in predialysis systolic and diastolic bloodin a hemodialysis center. Patients who dialyzed at home
pressures that occurred over the periods before and afterafter switching were more likely than patients who con-
patients switched from conventional hemodialysis totinued to dialyze in a center to have changed to daily
daily hemodialysis are shown in Figure 1 and Table 2.hemodialysis for lifestyle or employment reasons (57 vs.
There was a statistically significant reduction in both9%, P , 0.01), and less likely to have switched for better
systolic blood pressure (27 mm Hg, P 5 0.02) and dia-control of hypertension, avoidance of intradialytic hypo-
stolic blood pressure (24 mm Hg, P 5 0.02) at the timetension, or other medical reasons (40 vs. 74%, P 5 0.01).
of switch. This reduction was greater among the 49% of
patients receiving antihypertensive medications at theTrends in postdialysis weight
time of switch to daily hemodialysis; systolic blood pres-
The postdialysis weight declined by 0.44 kg (P 5 0.18) sure fell by 213 mm Hg (P , 0.01), and diastolic blood
during the six months that patients were treated with con- pressure fell by 27 mm Hg (P 5 0.02). There was no
ventional dialysis (Table 2). The mean postdialysis weight corresponding increase in these medications, but instead,
immediately prior to starting daily hemodialysis was 63.3 a statistically significant reduction in the number of anti-
kg. On starting daily hemodialysis, postdialysis weight hypertensive medications prescribed during the 12
months after switching to daily hemodialysis (Fig. 2).decreased by 0.63 kg (P 5 0.03), a reduction of 1.0%.
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Fig. 1. Predialysis systolic blood pressure (SBP) and diastolic blood
Fig. 3. Changes in predialysis serum albumin levels for patients (N 5pressure (DBP) in patients (N 5 72) from 6 months before until 12
68) from 6 months before until 12 months after starting daily hemodialy-months after starting daily hemodialysis. Plots show the mean SBP
sis. Plot shows the mean serum albumin level (d), the interquartileand DBP at each time point (d), the interquartile range (25th to 75th
range (25th to 75th percentiles), and the fitted line from the regressionpercentiles), and the fitted line from the regression model. SBP fell
model.7 mm Hg (P 5 0.02), and DBP fell 4 mm Hg (P 5 0.02) on starting
daily hemodialysis (time 0). The slopes of the fitted lines after start-
ing daily hemodialysis were not statistically different from zero (SBP 5
27 mm Hg per 6M, P 5 0.21; DBP 5 2 4 mm Hg per 6M, P 5 0.07).
(P , 0.001) to 4.35 g/dl at one year after changing hemo-
dialysis modality (Table 1 and Fig. 3).
The mean serum cholesterol was 183 mg/dl immedi-
ately prior to switching to daily hemodialysis. There were
no statistically significant trends in serum cholesterol
before or after increasing the dialysis frequency; no
change in level at the time of switch was observed.
Trends in hematocrit
There was no statistically significant trend in hemato-
crit levels during the six months before changing to daily
hemodialysis among all study patients (Table 2). The
mean hematocrit immediately prior to starting daily he-
modialysis was 27.9%. The hematocrit increased by 1.7
to 29.7% (P 5 0.002) after starting daily hemodialysis.
An apparent further increase in hematocrit during theFig. 2. Percentages of patients (N 5 72 at time 0) prescribed 0, 1, and
subsequent 12 months on daily hemodialysis of 0.9% per2 or more antihypertensive medications at 0 and 1 month before and
at 3, 6, and 12 months after starting daily hemodialysis. six months to a level of 31.5% at 12 months was not
statistically significant (P 5 0.3). Excluding four patients
who had a blood transfusion during either the 6 months
prior to changing to daily hemodialysis or in the 12The percentage of patients receiving no antihypertensive
months following the switch did not change these resultsmedications increased from 54 to 61% at six months and
substantially.75% at one year after the switch to daily hemodialysis.
Fifty-six patients were not receiving erythropoietin atThe fraction of patients receiving more than one antihy-
the time of change of treatment frequency. When thepertensive medication also decreased.
analysis was confined to these patients, hematocrit rose
Trends in serum albumin and cholesterol by 1.5% per six months (P 5 0.02) during the treatment
period with daily hemodialysis. Sixteen patients wereThe estimated parameters indicated that during the
receiving erythropoietin when they started daily hemodi-period of treatment with conventional hemodialysis, the
alysis; the median dose of erythropoietin was 8000 unitsserum albumin decreased by 0.18 g/dl per six months
per week at this time. Three months later, the median(P 5 0.01) to a mean level of 3.88 g/dl immediately prior
dose was 4000 units; at 6, 9, and 12 months, the medianto starting daily hemodialysis. The mean serum albumin
erythropoietin doses were 4000, 4000, and 5000 units,level rose 0.2 g/dl (P 5 0.004) on starting daily hemodial-
ysis, and thereafter, it rose by 0.1 g/dl per six months respectively.
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Fig. 5. Kaplan–Meier analysis of AV fistula survival among patientsFig. 4. Kaplan–Meier analysis of patient and technique survival starting
with a fistula on starting daily hemodialysis (N 5 63). AV fistula survivalwhen patients began daily hemodialysis (N 5 71). Patient survival was
was analyzed as the time from when patients started daily hemodialysisanalyzed as time until death; observations were censored at the end of
until an access thrombosis, infection, or surgery occurred or until thefollow-up or transplantation. At five years, 17 patients remained in the
access blood flow was inadequate for hemodialysis. Observations wereanalysis. Technique survival was analyzed as time until an unplanned
censored at death, transplantation, return to conventional hemodialysis,return to conventional hemodialysis or until death. Observations were
or the end of patient follow-up. At 24 months, 34 patients remained incensored at the end of follow-up, transplantation, or on planned switch
the analysis.back to conventional hemodialysis. At five years, 10 patients remained
in the analysis.
Vascular access use and patient hospitalization
Calcium phosphate metabolism The vascular access for dialysis immediately prior to
changing to daily hemodialysis was an arteriovenousThere were no significant changes in the average predi-
(AV) fistula for 64 patients (94.1%); three patients dia-alysis level of serum calcium or phosphate while the
lyzed via an AV graft (4.4%) and one by a catheterpatients were being treated with either conventional or
(1.5%). Access type was not recorded for four patients.daily hemodialysis. The proportion of patients who did
Seventeen (27%) of the 64 fistula patients dialyzed vianot require any medication to bind dietary phosphate
a single blood access needle, and 46 (72%) dialyzed viadid not change significantly over either treatment period.
two needles (percentages exclude one patient with an
unknown number of needles).Patient and technique survival
Prior to starting daily hemodialysis, there were 14 re-Kaplan–Meier survival curves of patient and technique
corded events in 12 patients, indicating an access failuresurvival for daily hemodialysis are shown in Figure 4.
during 606 months of follow-up (0.28 events per patient
Patient and technique survival differed between patients
year). After patients started daily hemodialysis, there were
dialyzed at home and in a dialysis center. Two-year pa-
13 events recorded in 11 patients, indicating an access
tient survival (independent of switching to conventional failure during 2864 months of follow-up (0.05 events per
hemodialysis) among those patients who dialyzed at patient year), which indicates a statistically significant
home was 100% and was 81% among those who dialyzed lower access failure rate with daily hemodialysis (P ,
in a dialysis center (P 5 0.02); overall patient survival was 0.001). Vascular access survival for patients with an AV
93% at two years. Two years after starting daily hemodial- fistula at the time of switch to daily hemodialysis was
ysis, 95% of patients dialyzed at home were still being 93% at two years after the switch, as shown in Figure 5.
treated with daily hemodialysis, compared with 54% of Survival analysis of hospitalization data showed that
patients who dialyzed in a dialysis center (P , 0.001). at two years after starting daily hemodialysis, 53% of
The overall two-year technique survival was 77%. patients had been admitted to a hospital at least once.
In a series of sensitivity analyses, patient survival was
Sensitivity analysesestimated after exclusion of the center in Catanzaro,
Italy, and also starting at one year after switching to Because the analyses of technique survival showed
daily hemodialysis. Patient survival after exclusion of that patients who dialyzed in a dialysis center were more
this center was 92% at two years. In a separate analysis likely to stop daily hemodialysis, a series of sensitivity
beginning one year after the switch, patient survival was analyses were performed to examine whether earlier
dropout among these patients altered the trends noted93% two years later.
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in blood pressure, postdialysis weight, hematocrit, and excess caused by the shorter interdialytic interval. Addi-
tionally, there was a 1.0% fall in the postdialysis weightserum albumin.
Among patients who dialyzed at home (N 5 42), the observed on changing to daily hemodialysis. Thus, the
increase in dialysis frequency likely allowed ultrafiltra-hematocrit rose by 0.4% per six months (P 5 NS) after
switching to more frequent hemodialysis (versus 0.9% tion to a lower postdialysis weight.
During the 12 months subsequent to starting dailyamong all patients). The rise in hematocrit was 0.9% per
six months (P 5 0.06) among those patients who dialyzed hemodialysis, there was a downward trend in systolic
and diastolic blood pressures that did not reach statisticalat home and who were not treated with erythropoietin
at the time of switch (vs. 1.5% among all 56 patients in significance. However, during the same period, the num-
ber of antihypertensive medications prescribed to pa-the study who were not treated with erythropoietin).
Serum albumin rose by 0.13 g/dl per six months (P 5 tients also decreased significantly, both clinically and
statistically. In the aggregate, the reduction in the inten-0.003), after switching to daily hemodialysis, among pa-
tients who dialyzed at home (vs. 0.1 g/dl among all pa- sity of treatment for hypertension combined with the
reduction in systolic and diastolic blood pressure sug-tients). Postdialysis weight rose by 0.4 kg per six months
(P 5 NS) in patients who dialyzed at home (same as gests a strong beneficial effect of daily hemodialysis on
the control of hypertension compared with conventionalamong all patients). Systolic blood pressure decreased
by 12 mm Hg (P , 0.001) within a month of switching to hemodialysis.
Charra et al have shown that prolonged three-timesdaily hemodialysis in patients who dialyzed at home (vs.
7 mm Hg among all patients). At the same time point, weekly hemodialysis resulted in improved blood pres-
sure control [12]. Prolonged hemodialysis likely allowsdiastolic blood pressure decreased significantly (P 5
0.001) by 6 mm Hg (vs. 4 mm Hg among all patients). a lower postdialysis weight to be achieved, without he-
modynamic instability, through use of low ultrafiltration
rates. Our results suggest that a similar effect can be
DISCUSSION
produced by daily hemodialysis with short, but frequent,
There is an increasing interest in daily hemodialysis periods of ultrafiltration, avoiding the degree of extracel-
as a means of allowing more physiological control of lular volume overload present with conventional three-
body fluid and electrolyte composition and of providing times weekly hemodialysis.
lower peak toxin levels without increasing total weekly Daily hemodialysis may also have advantages for pa-
dialysis duration. We present data from a series of 72 tients who have hemodynamic instability during conven-
patients, the majority of whom dialyzed at home, whose tional dialysis. Increasing the frequency of dialysis may
median dialysis frequency was increased on average from allow effective ultrafiltration without intradialytic hypo-
three to six treatments per week. The experience of nine tension. Sixteen percent of patients in our study switched
centers with switching 72 patients from conventional he- to daily hemodialysis to allow more frequent ultrafiltra-
modialysis to daily hemodialysis provides numerous new tion with the goal of avoiding hypotension. The number
insights. We observed changes in important clinical and of hypotensive events recorded per patient per month
biochemical parameters, both within one month of the showed a statistically significant decline after changing
change in dialysis frequency and then during the subse- to frequent hemodialysis.
quent 12 months.
Effect on hematocrit and biochemical measurements
Effect on control of hypertension The shortened interdialytic interval with daily hemodi-
Extracellular volume overload contributes substan- alysis leads to less volume excess predialysis. Thus, blood
tially to hypertension in hemodialysis patients, and im- samples taken prior to dialysis are likely less diluted in
proved achievement of “dry weight” allows better blood patients dialyzing more frequently. Additionally, we
pressure control. We found a reduction in both predial- have postulated that ultrafiltration to a lower postdialysis
ysis systolic and diastolic blood pressure within one weight may explain changes in blood pressure seen
month of starting daily hemodialysis. Subgroup analysis within one month of cross-over to daily hemodialysis.
showed that the greatest reduction in blood pressure on The combined effect of these processes may explain the
starting daily hemodialysis took place among patients changes in serum albumin and hematocrit seen shortly
requiring treatment with antihypertensive medications. after starting daily hemodialysis.
The reductions in blood pressure among patients not on Hematocrit. It has been reported that an increase in
antihypertensive medications were of smaller magnitude the dose of hemodialysis in patients with ESRD is associ-
and not statistically significant. ated with an increase in hematocrit [13, 14]. In our study,
These changes in predialysis systolic and diastolic overall, an apparent rise in hematocrit level on starting
blood pressure soon after switching to daily hemodialysis daily hemodialysis was not statistically significant. When
the analysis was limited to only those patients not treatedlikely reflect a reduction in predialysis extracellular fluid
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with erythropoietin, the hematocrit increase of 1.5% per Patient survival
six months during the first year of daily hemodialysis Overall, patient survival in this study was 93% at two
was statistically significant. Among patients treated with years after switching to daily hemodialysis. It is likely
erythropoietin, the dose prescribed was reduced after that this high survival rate in part reflects the effect of
starting daily hemodialysis, also suggesting an improve- selection of patients who switched to daily hemodialysis,
ment in their anemia and perhaps an increased respon- but who dialyzed at home. This hypothesis is supported
siveness to the drug. This finding may be related to better by the observed difference in two-year survival rates
control of uremia, as suggested previously [13]. This sug- between patients who dialyzed at home versus those who
gests that among erythropoietin-treated patients, the were treated with daily hemodialysis in a dialysis center
magnitude of the increase in the hematocrit associated (100 vs. 82%).
We have previously shown, in a random national sam-with more frequent dialysis would likely have been larger
ple of hemodialysis patients in the United States, thathad the dose of erythropoietin been kept constant. The
patients who start standard home hemodialysis arerate of blood transfusions before and after a change of
younger, have fewer comorbid conditions, and havehemodialysis frequency could also confound the rela-
higher serum albumin values when they start dialysistionship of dialysis method with hematocrit. The rate
[15]. In this study, patients who dialyzed at home whenof blood transfusions was higher before starting daily
they switched to daily hemodialysis were marginallyhemodialysis, and thus, the effect of such a potential bias
younger than patients dialyzing in a dialysis center (me-would reduce, rather than enhance, the observed effect
dian age 46 vs. 48.5 years). However, patients who dia-of dialysis method on hematocrit. Because only a few
lyzed at home were more likely to have changed to dailypatients received blood transfusions either before or
hemodialysis for lifestyle or employment reasons ratherafter starting daily hemodialysis, a confounding effect of
than medical reasons. They were less likely to haveblood transfusion is likely unimportant.
switched to allow better control of hypertension or toAlbumin. Low serum albumin is an important pre-
avoid intradialytic hypotension, suggesting that they haddictor of mortality in dialysis patients [4]. We found a
less cardiovascular comorbidity.statistically significant decline in serum albumin during
the six months of prior conventional hemodialysis. An Technique survival
early increase in serum albumin, after the change to daily
The fraction of patients remaining on the daily hemo-hemodialysis, was followed with a further increase in
dialysis schedule (technique survival) also was higherserum albumin during the next 12 months. Although the
for patients who dialyzed at home than for those whoincrease in serum albumin concentration within the first
dialyzed in a dialysis center (95 vs. 54% at two years).month of starting daily hemodialysis may reflect less
Poorer technique survival among patients dialyzing daily
dilution of the predialysis blood sample because of the
within a dialysis unit may reflect the increased time per
shorter interdialytic interval, the subsequent rise in se-
week spent traveling to and from the dialysis unit. We
rum albumin concentration over the next 12 months ap- found that with frequent hemodialysis, the total dialysis
pears to reflect an actual increase. This is supported by time per week was decreased, on average, by about 1.5
the observation that during this period, the postdialysis hours because the duration of each of the six sessions
weight was increasing, not falling. Both the increasing was slightly less than half that of the three sessions of
serum albumin concentration and postdialysis weight in- conventional hemodialysis. However, for those patients
dependently suggest that nutritional status improves with dialyzing in a center, the amount of time spent traveling
daily hemodialysis. to and from the dialysis unit would approximately double
Serum phosphate. Our data show no statistically sig- with daily hemodialysis. Data from Wave-2 of the U.S.
nificant changes in calcium or phosphate level before Renal Data System Dialysis Morbidity and Mortality
or after starting daily hemodialysis. We also found no Study, a national random sample of U.S. patients starting
statistically significant reduction in the number of phos- chronic hemodialysis during 1996, indicate that 56% of
phate binders prescribed to patients following the switch hemodialysis patients spend over 30 minutes traveling
to daily hemodialysis. Phosphate is poorly removed by to and from their dialysis unit for a single hemodialysis
hemodialysis. Pierratos, Ouwendyk, and Franceur re- treatment (F.K. Port, personal communication). The op-
cently reported that all 12 patients who started frequent portunity costs associated with this travel time for a
slow nocturnal home hemodialysis in their program were working hemodialysis patient dialyzing six times per
able to stop taking phosphate-binding medications [10]. week at a dialysis center are likely to be high. We feel
This observation may be explained by the substantially that daily hemodialysis in dialysis centers is likely to only
longer duration of dialysis ranging from 48 to 70 hours be an option for patients with easy access to a nearby
dialysis center. To avoid a substantial dropout rate fromper week.
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daily hemodialysis, it is likely that the majority of patients spective analysis is vulnerable to the effects of bias, con-
founding, and the effects of temporal changes in practicewill need to be trained to dialyze at home at times conve-
nient to their schedule. pattern. We have sought to address these issues in our
analyses.
Vascular access failure A major strength of this study is the cross-over design;
patients are their own controls. The analysis methodNinety-three percent of patients in this study had an
AV fistula for hemodialysis vascular access. This high preserves this matching, allowing the comparison of
blood pressure and laboratory data within individual pa-percentage reflects, in part, the practice in Europe and
likely the selection of younger, fitter, and nondiabetic tients between the periods of treatment with conven-
tional and daily hemodialysis.patients who have greater odds of receiving an AV fistula
[16]. We have no representative information on the deliv-
ered dose of dialysis for the cohort of patients as a largeFor most patients, daily hemodialysis requires a dou-
bling in the number of times per week dialysis needles majority started daily hemodialysis before the measure-
ment of delivered dose of hemodialysis became part ofare placed in the vascular access. A potential barrier to
introduction of the technique of daily hemodialysis is routine clinical practice. We did observe a reduction in
the total hemodialysis treatment time from 12 to 10.5the concern that the rate of access failure may be higher
because of trauma to the access as a result of more hours per week. Increasing the frequency of hemodialy-
sis is an effective way of increasing the dialysis efficiencyfrequent dialysis needle insertion. We did not find a
higher rate of vascular access failure among patients and likely offsets the reduction in total treatment time
per week [6]. In a study comparing daily hemodiafiltra-who switched to daily hemodialysis; rather, the reported
vascular access failure rate fell from a relatively low rate tion for nine hours per week to three times per week
conventional hemodiafiltration for 12 hours per week,(by U.S. standards) of 0.28 per patient year to 0.05 per
patient year after starting daily hemodialysis. the time averaged blood urea nitrogen concentration did
not change despite a 25% reduction in total treatmentWe also report vascular access survival among those
patients with an AV fistula. At one year, the AV fistula time per week [18]. Therefore, in our study, despite a
13% reduction in the total weekly hemodialysis treat-patency rate, without operative intervention, was 95%.
These results are superior to those shown previously for ment time, the total amount of urea removed per week
likely increased on starting daily hemodialysis. ClearanceAV fistula survival in a random national sample of U.S.
hemodialysis patients incident in 1990, even for a sub- of larger molecular weight substances may also be in-
creased with daily therapy. In the same study the timegroup of nondiabetic patients [17]. Our results of vascu-
lar access failure before and after switching to daily he- averaged concentration of b2 microglobulin decreased
by 42% on starting daily hemofiltration [18].modialysis and the AV fistula survival rate following
switch should be interpreted with caution. These data Unlike conventional three times per week hemodialy-
sis, there are no agreed standards on what constitutesare limited because of the small patient sample size; only
five patients actually had a reported access failure. an adequately delivered dose for daily hemodialysis. It is
clear that Kt/V values per treatment cannot be comparedWhy should the rate of AV fistula failure be low when
the vascular access is used twice as often? One possibility between conventional and more frequent hemodialysis
by summing over one week Kt/V values for individualis that AV fistula failure depends on the person cannulat-
ing the access. The majority of patients in this study treatments. The total weekly Kt/V required to remove
the same mass of urea is less for a patient dialyzed sixdialyzed at home and either they or their partner cannu-
lated the access. It may be that cannulation performed times per week than a patient dialyzed three times per
week [6]. Until standards for hemodialysis adequacy forconsistently by one person (the patient or their partner)
leads to fewer thrombotic or infectious complications daily hemodialysis have been derived from clinical stud-
ies, we would suggest that the delivered dose of hemodi-than cannulation by a series of dialysis unit personnel.
The observed reduction in hypotensive episodes during alysis for a patient treated on a daily schedule should
be unequivocally greater than the generally accepteddialysis may also reduce access failure from thrombosis
by avoiding reduced access blood flow. It is also possible U.S. minimum target of a Kt/V of 1.2. We would view
daily hemodialysis as an opportunity to provide a greaterthat the change to daily anticoagulation reduces the rate
of access thrombosis. dose of hemodialysis through increased efficiency. We
strongly caution against using the increased efficiency
Limitations of daily hemodialysis to reduce the total hemodialysis
treatment time per week.The data for this study were obtained from retrospec-
tive data collection. It was not a preplanned prospective We have postulated that on starting daily hemodialy-
sis, the delivered dose of dialysis increased leading to anstudy, and thus, there was no uniform protocol for
switching patients to daily hemodialysis. Such a retro- increase in hematocrit and serum albumin. The median
Woods et al: Daily hemodialysis 2475
predialysis blood urea nitrogen concentration among the to confirm our findings can be collected prospectively
cohort of patients was 98 mg/dl at three months before and disseminated to clinicians and patients.
starting daily hemodialysis. It is possible that during the
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